26638 Risk stratification of patients with stage I cutaneous melanoma (CM) using 31-gene expression profiling (GEP)

Abstract

Introduction: Up to 15% of patients with AJCC stage I CM are at risk for metastasis. The 31-GEP test for CM stratifies metastatic risk into low (Class 1A), intermediate (Class 1B/2A), or high (Class 2B), is an independent prognostic factor for CM recurrence, and when used with clinical factors, informs sentinel lymph node biopsy (SLNBx) recommendations and subsequent surveillance decisions.